Heparin
Anticoagulant. Prevents blood clot formation. Large molecule excluded from the brain. No direct brain effect — does not cross the blood–brain barrier.
Benefits
Fast-acting injectable anticoagulant that prevents and treats dangerous blood clots (DVT, PE) in medical settings.
Risks
Prescription-only; the main risk is bleeding, along with heparin-induced thrombocytopenia (HIT). Requires monitoring and professional administration.
Informational only — not medical advice.
Body systems
Organs
Research (6)
- Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis: A Randomized, Double-Blind, Active-Control, Phase 3 Study Agarwal et al. (2023) PubMed ↗
- Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials Frere et al. (2022) PubMed ↗
- Heparin and anticoagulation Onishi et al. (2016) PubMed ↗
- 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016 Liu et al. (2016) Full text ↗ PubMed ↗
- Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism Smythe et al. (2016) PubMed ↗
- Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety Hirsh et al. (2001) PubMed ↗
Community
Log in to rate and share your notes.
No contributions yet.